Abstract
BackgroundAlthough therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine...
Highlights
Therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine modalities that can adapt to current and future developments in cancer immunotherapy
The current study shows that fusion of Macrophage Inflammatory Protein-3α (MIP3α) to melanoma antigen gp100 enhances the immunogenicity and efficacy of a DNA vaccine in a therapeutic Mouse melanoma model (B16F10) mouse melanoma model
As was the case for the antibody concentration, the antigen-only vaccine elicited a moderate vaccine-specific CD8+ T-cell response that significantly differed from the mock vaccination by both percentage (p = 0.030; Fig. 1b) and total number (p < 0.001; Fig. 1c) of CD8+ T cells reactive to the immunogenic gp10025-33 peptide
Summary
Therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine modalities that can adapt to current and future developments in cancer immunotherapy. Previous published work has indicated that MIP-3α targets nascent peptides to immature dendritic cells, leading to processing by class I and II MHC pathways This platform has shown enhanced efficacy in prophylactic melanoma and therapeutic lymphoma model systems. They generate effector immunity from all three arms of the adaptive immune response, including CD8+ T-cells [6] They avoid the inclusion of extraneous and possible deleterious antigens that may be components of bacterial or viral-based vaccines [6]. DNA vaccines have shown efficacy in animals, with three licensed for veterinary use [12,13,14]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
